By the Top Tier Newswire AI Desk · October 2, 2026 at 11:50 AM ET · reviewed against 3 wire stories
IMMUNITYBIO INC (IBRX) is up +12.66% in the latest session. Our newswire has captured 3 stories on IBRX across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why IBRX stock is up today
ImmunityBio Inc (IBRX) surged 12.66% to $10.46 in a single session, marking one of the most significant moves in the stock over the past year. The rise came amid heightened investor attention driven by recent governance developments and a notable increase in call volume. The stock opened with a modest 1.7% gap up and continued to climb throughout the session, reaching an intraday high of $10.55 before closing near that level.
What Happened
The stock's upward movement was fueled by news that Linda Maxwell, M.D., a director of ImmunityBio, has taken on an additional board seat at HLS Therapeutics, a development highlighted in a recent HLS press release. This governance-related catalyst appears to have drawn investor interest, particularly in the context of ImmunityBio's recent regulatory milestones in the UAE for its lead drug ANKTIVA. Additionally, call volume for the stock has been above normal levels, with the direction of the trade being clearly bullish. The stock’s performance was further supported by a recent earnings report that beat estimates for both revenue and adjusted earnings per share.
What The Data Shows
The stock opened at $9.44 and closed at $10.46, with a session high of $10.55. The volume of 15.1 million shares was 1.4 times the 3-month average, indicating strong participation. Over the past eight sessions, the stock has risen 3.7% from $8.85 to $9.17. Recent insider transactions include two sales totaling $2.7 million in the last 90 days, with no insider buying reported. On the options front, unusual activity was noted with a put premium of $244K being the largest single print. The stock also printed 15 fresh 52-week highs on October 2, 2026.
What To Watch
Investors should continue to monitor the stock's volume and price action in the coming sessions, as well as any further developments related to ImmunityBio’s regulatory approvals and governance changes.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IBRX · Oct 2 session (5-min) · +10.88% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 3 stories · 60/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
1d agoMarketChameleonBULLISH 58General
IBRX Rises as Director Linda Maxwell Adds Another Board Seat After HLS Appointment
October 2, 2026
ImmunityBio (IBRX) traded higher during market hours as attention turned to a governance-related catalyst mentioned in an HLS Therapeutics board update. The HLS press release highlighted that Linda Maxwell, M.D.—already a director at IBRX where she chairs the Compensation Committee—has been appointed an independent director at HLS and will join its Audit Committee.
1d agoThe FlyBULLISH 62General
ImmunityBio call volume above normal and directionally bullish
1d agoThe FlyBULLISH 61General
ImmunityBio rises 11.6%
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →